Low-grade follicular lymphomas: Analysis of prognosis in a series of 281 patients

Pierre Soubeyran , Houchingue Eghbali , Françoise Bonichon , Monique Trojani , Pierre Richaud , Bernard Hœrni
{"title":"Low-grade follicular lymphomas: Analysis of prognosis in a series of 281 patients","authors":"Pierre Soubeyran ,&nbsp;Houchingue Eghbali ,&nbsp;Françoise Bonichon ,&nbsp;Monique Trojani ,&nbsp;Pierre Richaud ,&nbsp;Bernard Hœrni","doi":"10.1016/0277-5379(91)90425-D","DOIUrl":null,"url":null,"abstract":"<div><p>From 1963 to 1988, 281 patients with newly diagnosed follicular lymphomas were treated and followed at the Foundation Bergonié. Distribution of stages was: 72 I, 61 II, 83 III and 65 IV. Within stage III, two subgroups were retrospectively defined: stages III<sub>1</sub> (32 cases) included patients with less than 8 involved sites, only 1 or 2 above diaphragm, and no spleen or mediastinal enlargement. Stage III<sub>2</sub> (51 cases) included the remaining stage III cases. Median follow-up was 9 years. Complete remission (CR) rate was 82%. 10-year overall survival (OS) and time to treatment failure (TTF) rates were, respectively 38% and 29.5%. 10-year time to relapse (TTR) rate was 36%. Statistical analyses showed concordant results with two main prognostic factors: age (<span><math><mtext>&lt;60</mtext><mtext>&gt;60</mtext></math></span>) and stage (I to III<sub>1</sub>/III<sub>2</sub> and IV). Age was the most important factor for OS analysis and stage for CR and TTR analysis. This leads to only three prognostic groups with different outcome. The first includes younger patients (&lt;60 years) with limited stages (≤III<sub>1</sub>); the second, patients either older than 60 or with advanced stages; the last, elderly patients with advanced stages. CR rates of these three groups were, respectively 97%, 75% and 57%. 10-year OS were, respectively 73.5%, 27% and 0%; 10-year TTR were 54%, 22% and 0%. These results have lead to data which are easy to handle and which can help to establish a rationale for further prospective trials.</p></div>","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":"27 12","pages":"Pages 1606-1613"},"PeriodicalIF":0.0000,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90425-D","citationCount":"58","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Cancer and Clinical Oncology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/027753799190425D","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 58

Abstract

From 1963 to 1988, 281 patients with newly diagnosed follicular lymphomas were treated and followed at the Foundation Bergonié. Distribution of stages was: 72 I, 61 II, 83 III and 65 IV. Within stage III, two subgroups were retrospectively defined: stages III1 (32 cases) included patients with less than 8 involved sites, only 1 or 2 above diaphragm, and no spleen or mediastinal enlargement. Stage III2 (51 cases) included the remaining stage III cases. Median follow-up was 9 years. Complete remission (CR) rate was 82%. 10-year overall survival (OS) and time to treatment failure (TTF) rates were, respectively 38% and 29.5%. 10-year time to relapse (TTR) rate was 36%. Statistical analyses showed concordant results with two main prognostic factors: age (<60>60) and stage (I to III1/III2 and IV). Age was the most important factor for OS analysis and stage for CR and TTR analysis. This leads to only three prognostic groups with different outcome. The first includes younger patients (<60 years) with limited stages (≤III1); the second, patients either older than 60 or with advanced stages; the last, elderly patients with advanced stages. CR rates of these three groups were, respectively 97%, 75% and 57%. 10-year OS were, respectively 73.5%, 27% and 0%; 10-year TTR were 54%, 22% and 0%. These results have lead to data which are easy to handle and which can help to establish a rationale for further prospective trials.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
低级别滤泡性淋巴瘤:281例患者预后分析
从1963年到1988年,281名新诊断的滤泡性淋巴瘤患者在bergoni基金会接受了治疗和随访。分期分布为:72 I, 61 II, 83 III和65 IV。在III期中,回顾性定义了两个亚组:III期(32例)包括受累部位少于8个的患者,只有膈上方的1或2个,没有脾脏或纵隔肿大。iiii期(51例)包括剩余的III期病例。中位随访时间为9年。完全缓解(CR)率为82%。10年总生存率(OS)和治疗失败时间(TTF)分别为38%和29.5%。10年复发时间(TTR)为36%。统计分析结果与年龄(60岁)和分期(I ~ III1/III2和IV)两大预后因素一致,年龄是OS分析的最重要因素,CR和TTR分析的最重要因素是分期。这导致只有三个预后组有不同的结果。第一类包括分期有限(≤iii - 1)的年轻患者(60岁);第二组是60岁以上或晚期患者;最后,老年晚期患者。三组的CR率分别为97%、75%和57%。10年OS分别为73.5%、27%和0%;10年TTR分别为54%、22%和0%。这些结果产生了易于处理的数据,并有助于为进一步的前瞻性试验建立基础。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Preclinical evaluation of polymer-bound doxorubicin Corrections News Introduction Phase II study of weekly 5-fluorouracil, cisplatin and vinblastine in advanced non-small cell lung cancer
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1